Genus Oncology completes enrollment to the Phase Ib trial of GO-203 in combination with decitabine for patients with AML.
Based on an acceptable safety profile and promising clinical activity, the combination has now been advanced to a Phase IIa study at the BIDMC and DFCI to assess therapeutic efficacy.
Based on an acceptable safety profile and promising clinical activity, the combination has now been advanced to a Phase IIa study at the BIDMC and DFCI to assess therapeutic efficacy.
RSS Feed
